Testosterone Cypionate Overdose and Accidental Excess Dose

What Happens Physiologically When Testosterone Cypionate Is Overdosed

Testosterone cypionate overdose produces supraphysiologic androgen exposure through the same receptor pathways as therapeutic dosing, just at concentrations that push multiple organ systems past their compensatory limits. The androgen receptor (AR) is a nuclear transcription factor; when testosterone or its more potent metabolite dihydrotestosterone (DHT) binds it, the complex translocates to the nucleus and alters gene expression across muscle, bone, liver, brain, and hematopoietic tissue. At excess doses, those transcriptional effects become pathological rather than therapeutic.

Erythropoiesis and Polycythemia

The most clinically dangerous acute effect of excess testosterone is stimulation of erythropoiesis. Testosterone upregulates erythropoietin (EPO) production in the kidney and directly stimulates erythroid progenitor cells in bone marrow [1]. A hematocrit above 54% substantially raises whole-blood viscosity and venous thromboembolism (VTE) risk. The Endocrine Society's 2018 guideline on male hypogonadism specifies that TRT should be withheld when hematocrit exceeds 54% [2].

Aromatization and Estrogen Excess

Surplus testosterone undergoes aromatase-mediated conversion to estradiol, especially in adipose tissue. Supraphysiologic estradiol produces gynecomastia, fluid retention, and suppression of the hypothalamic-pituitary-gonadal (HPG) axis [3]. Elevated estradiol also worsens lipid profiles, raising LDL and reducing HDL [4].

Hepatic and Cardiovascular Effects

Injectable testosterone cypionate does not carry the same first-pass hepatotoxicity risk as 17-alpha alkylated oral androgens, but supraphysiologic levels still alter hepatic lipid metabolism. A 2023 meta-analysis in JAMA Network Open (N=5,601 patients across 19 RCTs) found that testosterone therapy was associated with increased major adverse cardiovascular events in men with pre-existing cardiovascular disease [5]. The TRAVERSE trial (N=5,246, mean age 63.7 years) published in NEJM in 2023 found a non-inferior cardiovascular safety profile at replacement doses but specifically excluded men who received doses producing supraphysiologic testosterone levels [6].

CNS and Psychiatric Effects

High-dose androgen exposure alters dopaminergic and serotonergic signaling. Published case series document aggression, hypomania, and in rare cases psychosis at supraphysiologic testosterone concentrations [7]. The mechanism likely involves AR-mediated gene expression in the limbic system combined with elevated neurosteroid metabolites [8].

How Testosterone Cypionate Works at Therapeutic Doses

Understanding the overdose picture requires a firm grasp of normal pharmacology.

Mechanism of Action

Testosterone cypionate is testosterone attached to a cypionate ester, which slows absorption from the injection depot into systemic circulation [9]. Once the ester is cleaved by plasma esterases, free testosterone enters target cells passively. Inside the cell, testosterone may act directly on the AR or be converted to DHT by 5-alpha reductase (more potent AR agonist) or to estradiol by aromatase. The testosterone-AR complex then acts as a transcription factor, regulating genes governing muscle protein synthesis, red blood cell production, bone mineralization, and sexual function [10].

Pharmacokinetics

After a single 200 mg intramuscular injection, serum testosterone peaks at roughly 24 to 48 hours and returns toward baseline over 10 to 14 days. The elimination half-life of the cypionate ester is approximately 8 days [11]. Subcutaneous administration produces lower, flatter peaks with similar total drug exposure. Testosterone is 98% protein-bound (to sex hormone-binding globulin and albumin) in circulation, which means that measuring total testosterone captures both free and bound fractions; free testosterone is the biologically active component [12].

Clinical Efficacy at Standard Doses

The T-Trials (N=790 hypogonadal men aged 65 or older) published in NEJM 2016 demonstrated that testosterone therapy improved sexual desire, erectile function, and self-reported sexual activity versus placebo at 12 months [13]. The Physical Function Trial within T-Trials showed modest improvement in 6-minute walk distance (average gain of 30 meters vs. Placebo). These benefits occurred at doses titrated to produce testosterone levels in the mid-normal range (approximately 500 ng/dL), not supraphysiologic levels [13].

Defining Overdose: What Counts as Excess Dosing

"Overdose" in the testosterone cypionate context covers several clinical scenarios with different urgency levels.

Scenario 1: Double-Injection Error

A patient injects twice in one week instead of once, or draws double the prescribed volume. This is the most common accidental excess scenario seen in telehealth TRT practices. A single doubled dose (e.g., 400 mg instead of 200 mg) in a 90 kg man will produce a testosterone peak of roughly 1,800 to 2,400 ng/dL based on pharmacokinetic modeling, well above the upper limit of normal (1,050 ng/dL per most laboratory reference ranges) [14].

Scenario 2: Compounding or Concentration Error

Compounded testosterone cypionate vials are available in concentrations ranging from 100 mg/mL to 400 mg/mL. A patient accustomed to drawing 1 mL of a 200 mg/mL product who switches to a 400 mg/mL vial without adjusting volume doubles their dose with no change in injection behavior. This type of error is documented in FDA MedWatch reports [15].

Scenario 3: Intentional Supraphysiologic Dosing

Anabolic steroid misuse involves doses of 300 to 1,000 mg or more per week, far exceeding the 50 to 200 mg/week therapeutic range. The adverse event profile in this population is substantially more severe and includes left ventricular hypertrophy, hepatic steatosis, severe dyslipidemia, and infertility [16].

Scenario 4: Accumulation Over Weeks

Weekly injections without adequate monitoring can produce progressive testosterone accumulation if the dose is even modestly above the patient's metabolic clearance capacity. Lab work drawn at trough (just before the next injection) may appear acceptable while peak levels are supraphysiologic [17].

Immediate Clinical Management of Testosterone Cypionate Overdose

No pharmacologic antidote exists for testosterone cypionate overdose. Management is supportive and guided by which physiologic systems are most affected.

Step 1: Confirm the Dose and Timing

Obtain a complete medication history. Establish the exact amount injected, the time since injection, and any prior excess dosing episodes. Serum total testosterone drawn within 24 to 48 hours of the excess dose will confirm supraphysiologic exposure [18].

Step 2: Order the Core Lab Panel

The minimum urgent panel includes:

• Total testosterone and free testosterone
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel
• Lipid panel
• Estradiol (E2)
• LH and FSH (will be suppressed at supraphysiologic testosterone)
• PSA (in men over 40) [2]

The FDA prescribing information for testosterone cypionate injection lists polycythemia and increased hematocrit among adverse reactions requiring dose interruption [19].

Step 3: Manage Polycythemia

A hematocrit above 54% requires immediate dose hold. Therapeutic phlebotomy (removal of 450 to 500 mL whole blood) reduces hematocrit acutely and may be indicated for levels above 56% with symptoms of hyperviscosity (headache, visual changes, tinnitus) [2]. The Endocrine Society guideline states: "We recommend checking hematocrit at baseline, at 3 to 6 months, and then annually. If the hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea" [2].

Step 4: Address Cardiovascular Risk

Supraphysiologic testosterone exposure in men with pre-existing cardiovascular disease warrants cardiology consultation. The TRAVERSE trial investigators noted that men with elevated testosterone levels were excluded from the primary efficacy analysis precisely because supraphysiologic exposure confounds both benefit and safety assessments [6]. Symptomatic hypertension or chest pain requires urgent evaluation.

Step 5: Psychiatric Assessment

Patients reporting significant mood changes, aggression, or sleep disturbance after excess dosing may benefit from psychiatric screening. Most symptoms resolve as testosterone levels normalize over 2 to 4 weeks after the last injection [7].

Step 6: Restart Protocol

After a single accidental double dose in a healthy man, the next injection is typically held for 1 to 2 weeks while labs are rechecked. The dose is then restarted at the correct prescribed amount. If hematocrit was elevated, dose reduction (e.g., from 200 mg to 100 mg weekly) is appropriate before resuming [20].

Monitoring Timeline After Accidental Excess Dose

The following post-overdose monitoring framework reflects synthesis of the Endocrine Society 2018 guideline [2], the FDA prescribing label [19], and published pharmacokinetic modeling data for testosterone cypionate [11]:

| Timepoint | Action | Key Labs | |-----------|--------|----------| | Day 1 to 2 (within 48 h of excess dose) | Confirm exposure, assess symptoms | Total T, CBC, metabolic panel | | Day 7 | Recheck hematocrit, assess cardiovascular symptoms | CBC, estradiol | | Week 2 to 3 | Trough testosterone to guide dose restart timing | Total T, free T, LH/FSH | | Week 4 to 6 | Restart at corrected dose, baseline reestablishment | Full panel including lipids, PSA | | 3 months post-restart | Confirm stable therapeutic range | Total T, hematocrit |

A trough testosterone below 400 ng/dL at week 2 to 3 generally indicates the excess dose has cleared and restart is safe, assuming hematocrit has normalized [2].

Specific Complications and Their Management

Venous Thromboembolism

VTE risk rises with polycythemia. A 2019 cohort study in Annals of Internal Medicine (N=39,936 testosterone-treated men) found that testosterone therapy was associated with a 1.5-fold increase in VTE risk in the 90 days after treatment initiation or dose escalation [21]. Confirmed DVT or PE requires anticoagulation and permanent discontinuation of testosterone therapy until thrombophilia workup is complete [2].

Gynecomastia

Symptomatic gynecomastia from aromatization of excess testosterone may require aromatase inhibitor (AI) therapy (anastrozole 0.5 to 1 mg twice weekly or exemestane 12.5 mg three times weekly) on a short-term basis while testosterone levels normalize [22]. Chronic AI use at supraphysiologic testosterone doses is not recommended as a long-term management strategy for compounding excess dosing errors [23].

Hypertension

Testosterone-related fluid retention and erythrocytosis can raise systolic blood pressure by 5 to 10 mmHg at excess doses [24]. First-line management is dose reduction and sodium restriction. If systolic pressure exceeds 160 mmHg, antihypertensive therapy and urgent internal medicine evaluation are warranted [25].

Infertility and HPG Axis Suppression

Exogenous testosterone suppresses LH and FSH, dramatically reducing intratesticular testosterone and spermatogenesis. After excess dosing, LH and FSH may remain suppressed for 4 to 12 weeks or longer [26]. For men seeking fertility preservation, human chorionic gonadotropin (hCG) 500 to 1,000 IU subcutaneously three times weekly may help maintain intratesticular testosterone during and after the recovery period [27].

Sleep Apnea Exacerbation

Testosterone worsens obstructive sleep apnea through androgen-mediated effects on upper airway musculature [28]. Supraphysiologic levels may precipitate or worsen existing OSA. Patients reporting new or worsened snoring, witnessed apneas, or daytime somnolence after excess dosing warrant polysomnography referral [2].

Who Is at Highest Risk for Serious Complications

Not every excess dose creates equal danger. Risk stratification matters clinically.

High-Risk Patients

Men with baseline hematocrit above 48%, known cardiovascular disease, a history of VTE, untreated sleep apnea, or prostate cancer are at substantially elevated risk for serious adverse events from even modest excess dosing [2]. The Endocrine Society identifies these conditions as either absolute or relative contraindications to testosterone therapy [2]. The FDA label for testosterone cypionate injection explicitly lists breast cancer and prostate cancer as contraindications [19].

Lower-Risk Patients

Healthy men under 50 with a single accidental double dose and no cardiovascular risk factors are generally manageable outpatient with close lab monitoring. Serum testosterone above 1,500 ng/dL with a hematocrit below 50% and no symptoms typically requires observation and dose hold rather than emergency intervention [20].

Age-Related Considerations

The T-Trials enrolled men 65 and older, a population with higher baseline cardiovascular and thrombotic risk [13]. For older men on TRT, even a single excess dose warrants more aggressive monitoring given the compressed safety margin in this age group [6].

Testosterone Cypionate in Context: Why Accurate Dosing Matters

Standard therapeutic testosterone cypionate produces serum levels in the 400 to 800 ng/dL range when dosed correctly, consistent with the normal physiologic range for adult men [2]. The T-Trials demonstrated meaningful clinical benefits at these replacement-range concentrations, with improvement in sexual function scoring (International Index of Erectile Function composite score increased by 2.64 points versus 0.15 for placebo, P<0.001) [13]. Benefits at supraphysiologic doses are not proportionally greater, but adverse events are. A 2016 FDA Drug Safety Communication reinforced the requirement for labeling changes on all testosterone products to reflect the cardiovascular and VTE risk, regardless of the indication [15].

Dosing precision matters. Draw technique, syringe dead-space, and concentration verification before each injection are practical steps that prevent the accidental excess exposures that drive the most avoidable adverse events in outpatient TRT [17].

The Endocrine Society guideline states: "We suggest against using testosterone therapy in men who are actively trying to father a child, have a haematocrit greater than 50%, have untreated severe obstructive sleep apnoea, have uncontrolled heart failure, or have experienced a myocardial infarction or stroke within the previous 6 months" [2].